دورية أكاديمية
Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion.
| العنوان: | Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion. |
|---|---|
| المؤلفون: | Tempescul A; Department of Clinical Haematology, Institute of Oncology and Haematology, CHRU morvan, Brest, France.; INSERM ESPRI ERI29 Laboratory of Immunotherapy and B Cell Diseases, Reseau Epigenetique et Reseau Canaux Ioniques du Cancéropole Grand Ouest, Brest, France., Bagacean C; INSERM ESPRI ERI29 Laboratory of Immunotherapy and B Cell Diseases, Reseau Epigenetique et Reseau Canaux Ioniques du Cancéropole Grand Ouest, Brest, France., Riou C; Department of Clinical Haematology, Institute of Oncology and Haematology, CHRU morvan, Brest, France.; INSERM ESPRI ERI29 Laboratory of Immunotherapy and B Cell Diseases, Reseau Epigenetique et Reseau Canaux Ioniques du Cancéropole Grand Ouest, Brest, France., Bendaoud B; INSERM ESPRI ERI29 Laboratory of Immunotherapy and B Cell Diseases, Reseau Epigenetique et Reseau Canaux Ioniques du Cancéropole Grand Ouest, Brest, France.; Laboratory of Immunology and Immunotherapy, CHRU Morvan, Brest, France., Hillion S; INSERM ESPRI ERI29 Laboratory of Immunotherapy and B Cell Diseases, Reseau Epigenetique et Reseau Canaux Ioniques du Cancéropole Grand Ouest, Brest, France.; Laboratory of Immunology and Immunotherapy, CHRU Morvan, Brest, France., Debant M; INSERM ESPRI ERI29 Laboratory of Immunotherapy and B Cell Diseases, Reseau Epigenetique et Reseau Canaux Ioniques du Cancéropole Grand Ouest, Brest, France., Buors C; Laboratory of Hematology, CHRU Cavale Blanche, Brest, France., Berthou C; Department of Clinical Haematology, Institute of Oncology and Haematology, CHRU morvan, Brest, France.; INSERM ESPRI ERI29 Laboratory of Immunotherapy and B Cell Diseases, Reseau Epigenetique et Reseau Canaux Ioniques du Cancéropole Grand Ouest, Brest, France., Renaudineau Y; INSERM ESPRI ERI29 Laboratory of Immunotherapy and B Cell Diseases, Reseau Epigenetique et Reseau Canaux Ioniques du Cancéropole Grand Ouest, Brest, France.; Laboratory of Immunology and Immunotherapy, CHRU Morvan, Brest, France. |
| المصدر: | European journal of haematology [Eur J Haematol] 2016 Mar; Vol. 96 (3), pp. 229-35. Date of Electronic Publication: 2015 May 20. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005->: Oxford : Blackwell Original Publication: Copenhagen : Munksgaard, c1987- |
| مواضيع طبية MeSH: | Antibodies, Monoclonal/*pharmacology , Antineoplastic Agents/*pharmacology , B-Lymphocytes/*drug effects , B-Lymphocytes/*immunology , Complement C4/*immunology , Leukemia, Lymphocytic, Chronic, B-Cell/*immunology, Adolescent ; Adult ; Aged ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/therapeutic use ; B-Lymphocytes/metabolism ; Biomarkers ; Child ; Child, Preschool ; Combined Modality Therapy ; Complement C3/immunology ; Female ; Humans ; Immunophenotyping ; Infant ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Lymphocyte Depletion ; Male ; Middle Aged ; Polymorphism, Genetic ; Receptors, IgG/genetics ; Treatment Outcome ; Young Adult |
| مستخلص: | The management of patients with chronic lymphocytic leukaemia (CLL) has improved with the utilisation of ofatumumab as a novel anti-CD20 monoclonal antibody. However, as half of the patients fail to respond to the treatment, the aim of this study was to evaluate circulating CLL cell depletion and clinical response according to the context of complement activation and FcγRIIIA polymorphism in ten CLL patients with relapsed/refractory disease. At the end of the treatment, results indicated that circulating CD5(+) CD19(+) CLL cell depletion was major (<0.01 × 10(9) /L) in 4 of 10 patients, partial (>50% decrease) in 4 of 10 patients and ineffective for the two other patients. No clinical modifications were observed following ofatumumab introduction. Ofatumumab administration leads to a rapid and important exhaustion of complement C4 levels in patients with initial lymphocytosis. C4 exhaustion was accelerated in a non-responder patient, and incomplete in two patients with partial circulating depletion. Moreover, delaying weekly to monthly ofatumumab injections improved CLL cell depletion in two patients. FcγRIIIA 158 polymorphism (FF n = 6 and VF n = 4) was not associated with major and/or partial circulating CLL cell depletion. In conclusion, ofatumumab induces an important C4 exhaustion that needs to be taken into account when treating CLL patients with ofatumumab. (© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.) |
| فهرسة مساهمة: | Keywords: FcγRIII polymorphism; chronic lymphocytic leukaemia; complement; ofatumumab |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Antibodies, Monoclonal, Humanized) 0 (Antineoplastic Agents) 0 (Biomarkers) 0 (Complement C3) 0 (Complement C4) 0 (FCGR3A protein, human) 0 (Receptors, IgG) M95KG522R0 (ofatumumab) |
| تواريخ الأحداث: | Date Created: 20150428 Date Completed: 20161213 Latest Revision: 20191210 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1111/ejh.12573 |
| PMID: | 25911969 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1600-0609 |
|---|---|
| DOI: | 10.1111/ejh.12573 |